Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22+ acute lymphoblastic leukemia: results of the phase IB ITCC-059 trial

Autor: Edoardo Pennesi, Erica Brivio, Anneke C. J. Ammerlaan, Yilin Jiang, Vincent H. J. van der Velden, H. Berna Beverloo, Barbara Sleight, Franco Locatelli, Benoit Brethon, Claudia Rossig, Gernot Engstler, Anna Nilsson, Benedicte Bruno, Arnaud Petit, Bella Bielorai, Carmelo Rizzari, Fanny Rialland, Alba Rubio-San-Simón, Francisco J. Bautista Sirvent, Cristina Diaz-de-Heredia, Susana Rives, Christian M. Zwaan

Publikováno v: Haematologica, Vol 999, Iss 1 (2024)

Inotuzumab Ozogamicin (InO) is a CD22-directed antibody conjugated with calicheamicin. The Phase 1B of the ITCC-059 trial tested InO combined with chemotherapy in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Relapsed /refractory

Externí odkaz: https://doaj.org/article/c0f7af8ee2a94f19b2f8e805c1f3d42c

Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial

Autor: Edoardo Pennesi, Naomi Michels, Erica Brivio, Vincent H. J. van der Velden, Yilin Jiang, Adriana Thano, Anneke J. C. Ammerlaan, Judith M. Boer, H. Berna Beverloo, Barbara Sleight, Ying Chen, Britta Vormoor-Bürger, Susana Rives, Bella Bielorai, Claudia Rössig, Arnaud Petit, Carmelo Rizzari, Gernot Engstler, Jan Starý, Francisco J. Bautista Sirvent, Christiane Chen-Santel, Benedicte Bruno, Yves Bertrand, Fanny Rialland, Geneviève Plat, Dirk Reinhardt, Luciana Vinti, Arend Von Stackelberg, Franco Locatelli, Christian M. Zwaan

Publikováno v: Leukemia
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname
Leukemia, 36(6), 1516-1524. Nature Publishing Group

Inotuzumab Ozogamicin is a CD22-directed antibody conjugated to calicheamicin, approved in adults with relapsed or refractory (R/R) B cell acute lymphoblastic leukemia (BCP-ALL). Patients aged 1–18 years, with R/R CD22 + BCP-ALL were treated at the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33daf3144da595f4e65dbc30299e722a
https://doi.org/10.1038/s41375-022-01576-3

VZV Prophylaxis After Allogeneic Hematopoietic Stem Cell Transplantation in Children: When to Stop?

Autor: Eva deBerranger, Anne‐Flore Derache, Nassima Ramdane, Julien Labreuche, Pauline Navarin, Fanny Gonzales, Wadih Abou‐Chahla, Brigitte Nelken, Bénédicte Bruno

Publikováno v: Cancer Reports, Vol 7, Iss 11, Pp n/a-n/a (2024)

ABSTRACT Background Acyclovir treatment is an efficient prophylaxis to prevent varicella‐zoster virus (VZV) reactivation after allogeneic hematopoietic stem cell transplantation (HSCT). Aims This single center retrospective study tried to determine

Externí odkaz: https://doaj.org/article/4ca920f2089d45bb8c2e4dcb930b3e1e

Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease

Autor: Zeiser, R., von Bubnoff, N., Butler, J., Mohty, M., Niederwieser, D., Or, R., Szer, J., Wagner, E. M., Zuckerman, T., Mahuzier, B., Xu, J., Wilke, C., Gandhi, K. K., Socie, G, Sung-Soo, Yoon, Chulwon, Jung, Tobias, Gedde-Dahl, Marwan, Shaheen, Jose Antonio Perez Simon, Jose Valentin Garcia Gutierrez, Jaime Sanz Caballer, Rafael Duarte Palomino, David Valcarcel Ferreiras, Cristina Diaz de Heredia Rubio, Kwon, Mi, Maria Del Carmen Martinez Munoz, Soledad, Gonzalez, Matilde Rodriguez Ruiz, Inmaculada Heras Fernando, Maria Pascual Cascon, Ana Sastre Urgelles, Marta Gonzalez Vicent, Jose Maria Fernandez Navarro, Yvonne, Björk, Kristina, Carlson, Jih-Luh, Tang, Su-Peng, Yeh, Ronjon, Chakraverty, Robert, Wynn, Lajos, Floro, Brian Thomas Kornblit, Jason, Butler, David, Ritchie, John, Kwan, Jacqueline, Fleming, Duncan, Purtill, Georg, Hopfinger, Hildegard, Greinix, Johannes, Clausen, Dennis, Kim, Natasha, Kekre, Imran, Ahmad, Brian, Leber, Andrew, Daly, Gizelle, Popradi, Jennifer, White, Mohamed, Elemary, Gerard, Socie, Valérie, Coiteux, Patrice, Chevallier, Claude-Eric, Bulabois, Helene, Labussiere-Wallet, Mohamad, Mohty, Pierre-Simon, Rohrlich, Edouard, Forcade, Fabrice, Larosa, Sylvie, Francois, Stephanie N'Guyen Quoc, Marie-Therese, Rubio, Jean-Hughes, Dalle, Marie, Ouachee-Chardin, Benedicte, Bruno, Anne, Huynh, Nathalie, Fegueux, Jerome, Cornillon, Pascal, Turlure, Nikolas von Bubnoff, Georg-Nikolaus, Franke, Friedrich, Stoelzel, Matthias, Eder, Arne, Brecht, Nicolaus, Kroeger, Nina-Kristin, Steckel, Eva, Wagner, Guido, Kobbe, Wolfgang, Bethge, Matthias, Stelljes, Donald, Bunjes, Igor, Blau, Ingo, Mueller, Stefan, Klein, Christoph, Schmid, Lena, Oevermann, Herrad, Baurmann, Inken, Hilgendorf, Klaus Daniel Stachel, Yok-Lam, Kwong, Ron, Ram, Batya, Avni, Moshe, Yeshurun, Tsila, Zuckerman, Riccardo, Saccardi, Paolo, Corradini, Franco, Locatelli, Alessandro, Rambaldi, Andrea, Bacigalupo, Attilio, Olivieri, Francesca, Patriarca, Giovanni, Grillo, Francesca, Bonifazi, Edoardo, Lanino, Attilio, Rovelli, Benedetto, Bruno, Russo, Domenico, Maurizio, Musso, Marco, Zecca, Franca, Fagioli, Angelo Michele Carella, Stefania, Bregante, Roberto, Sorasio, Takanori, Teshima, Koichi, Miyamura, Kiyoshi, Ando, Hirohisa, Nakamae, Yoshinobu, Maeda, Tadakazu, Kondo, Masaya, Okada, Kazuhiko, Kakihana, Koji, Kato, Yasushi, Onishi, Kentaro, Fukushima, Shuichi, Taniguchi, Takehiko, Mori, Takayuki, Ishikawa, Yoshihiro, Inamoto, Kuball, J, A Lindemans, C, Jan, Vydra, Achilleas, Anagnostopoulos, Zubeyde, Ozkurt, Zafer, Gulbas, Seckin, Cagirgan, Sinem Civriz Bozdag, Penka, Ganeva, Dobrin, Konstantinov, Kazimierz, Halaburda, Jan, Zaucha, Gergely KrivÃ, N, Isabelina, Ferreira, Joao Forjaz de Lacerda, Alexey, Maschan, Elena, Parovichnikova

Acute graft-versus-host disease (GVHD) remains a major limitation of allogeneic stem-cell transplantation; not all patients have a response to standard glucocorticoid treatment. In a phase 2 trial, ruxolitinib, a selective Janus kinase (JAK1 and JAK2

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4b695b267a2a6439599dcd2674f979a
http://hdl.handle.net/11379/531211

Successful outcome of disseminated mucormycosis in a 3-year-old child suffering from acute leukaemia: the role of isavuconazole? A case report

Autor: Marjorie Cornu, Bénédicte Bruno, Séverine Loridant, Pauline Navarin, Nadine François, Fanny Lanternier, Elisa Amzallag-Bellenger, François Dubos, Françoise Mazingue, Boualem Sendid

Publikováno v: BMC Pharmacology and Toxicology, Vol 19, Iss 1, Pp 1-5 (2018)

Abstract Background The use of isavuconazole is approved for the management of invasive aspergillosis and mucormycosis, only in adults, as no paediatric pharmacology studies have been reported to date. Very few paediatric cases have been published co

Externí odkaz: https://doaj.org/article/634d9ecb986a42bb9b7d535d9a5cc91d